Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor

1. A method of delaying, reversing or slowing the progression of a cholestatic disease selected from the group consisting of chronic cholangiopathies, primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), biliary atresia and progressive familial intrahepatic cholestasis type 3 (PFIC3), comprising administering to a subject in need of treatment a therapeutically effective amount of a combination product comprising:

(i) elafibranor, a pharmaceutically acceptable salt or a solvate thereof; and

(ii) an ACC inhibitor selected from the group consisting of Gemcabene, CP-640186, MK-4074, PF05221304, GS-0976 and a pharmaceutical salt thereof.

2. The method according to claim 1 wherein component (i) is elafibranor.